Zealand Pharma A/S (OTCMKTS:ZLDPF) Releases Earnings Results, Misses Estimates By $0.96 EPS

Posted by Stephan Jacobs on May 8th, 2026

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) announced its earnings results on Thursday. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.96), Zacks reports. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.50%. The firm had revenue of $5.33 million for the quarter, compared to analyst estimates of $3.77 million.

Zealand Pharma A/S Stock Performance

Shares of OTCMKTS ZLDPF traded down $0.76 during mid-day trading on Friday, hitting $53.52. The company had a trading volume of 671 shares, compared to its average volume of 2,067. The company has a debt-to-equity ratio of 0.02, a current ratio of 23.57 and a quick ratio of 23.57. The business’s 50-day simple moving average is $46.61 and its 200-day simple moving average is $62.88. Zealand Pharma A/S has a 12 month low of $35.93 and a 12 month high of $83.12. The firm has a market cap of $3.83 billion, a P/E ratio of 3.97 and a beta of 0.87.

Analyst Ratings Changes

ZLDPF has been the topic of several recent analyst reports. BNP Paribas Exane downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Finally, William Blair reaffirmed a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Three investment analysts have rated the stock with a Strong Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

View Our Latest Stock Analysis on Zealand Pharma A/S

Zealand Pharma A/S Company Profile

(Get Free Report)

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.